{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:06:20Z","timestamp":1779509180394,"version":"3.53.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7182-26","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:09:43Z","timestamp":1779487783000},"source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Treatment Time Toxicity on Regimen Selection in Multiple Myeloma: A Single-Center Retrospective Study"],"prefix":"10.2169","author":[{"given":"Kensuke","family":"Hachiya","sequence":"first","affiliation":[{"name":"Department of Hematology, Matsusaka Chuo General Hospital, Japan"},{"name":"Department of Signal Transduction, Research Institute for Microbial Diseases, the University of Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohmei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsusaka Chuo General Hospital, Japan"},{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsusaka Chuo General Hospital, Japan"},{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsusaka Chuo General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Masuya","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan"},{"name":"Course of Nursing Science, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.","DOI":"10.1056\/NEJMra1011442"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica 105: 2358-2367, 2020.","DOI":"10.3324\/haematol.2020.247015"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Langseth \u00d8O, Myklebust T, Johannesen TB, Hjertner \u00d8, Waage A.  Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol 191: 418-425, 2020.","DOI":"10.1111\/bjh.16674"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2: e408-416, 2015.","DOI":"10.1016\/S2352-3026(15)00151-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ureshino H, Kamachi K, Kimura S. Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. Lancet Haematol 6: e498, 2019.","DOI":"10.1016\/S2352-3026(19)30168-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ruotsalainen J, Lehmus L, Putkonen M, Lievonen J, Kallio A, Raittinen P, et al. Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study. Ann Hematol 103: 1273-1284, 2024.","DOI":"10.1007\/s00277-023-05571-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, et al. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol 11: 1153-1168, 2015.","DOI":"10.2217\/fon.15.9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374: 1621-1634, 2016.","DOI":"10.1056\/NEJMoa1516282"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Durbin SM, Lundquist DM, Pelletier A, Jimenez R, Petrillo L, Kim J, et al. Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants. JCO Oncol Pract 20: 1252-1262, 2024.","DOI":"10.1200\/OP.23.00811"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gupta A, Eisenhauer EA, Booth CM. The Time Toxicity of Cancer Treatment. J Clin Oncol 40: 1611-1615, 2022.","DOI":"10.1200\/JCO.21.02810"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Itani Y, Obama K, Fujimori M, Saito J, Uchitomi Y. Cancer treatment-related financial toxicity in Japan: a scoping review. Front Psychol 14: 1205016, 2023.","DOI":"10.3389\/fpsyg.2023.1205016"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14: 1055-1066, 2013.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49: 1373-1379, 1996.","DOI":"10.1016\/S0895-4356(96)00236-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-718, 2007.","DOI":"10.1093\/aje\/kwk052"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7182-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:40:49Z","timestamp":1779507649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7182-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":14,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7182-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7182-26"}}